ArticleFrontiers in immunology2026
Combined treatment of benznidazole with an electrolyzed oxidizing water against
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising reports of drug resistance in Methods: Forty female BALB/c mice were infected intraperitoneally with 150 blood trypomastigotes of the Results: The BZN+EOW regimen achieved a 99.2% reduction in parasitemia and a 100% survival rate. Although the combination did not statistically surpass BZN monotherapy in absolute parasite clearance, it promoted significant clinical recovery, with weight gain exceeding 50% compared to the untreated infected group. Immunologically, the combination triggered a robust Th1-type immune profile response during the acute phase (40 dpi). By 365 dpi, this response shifted toward a more counterbalanced Th1/Th2 immune microenvironment, correlating with minimal and non-severe histopathological alterations in cardiac and skeletal tissues. Discussion: These findings suggest that BZN+EOW therapy preserved the trypanocidal efficacy observed with the monotherapy, yet it presented the added advantage of subtly refining the inflammatory landscape in the chronic phase. This balanced immune response could help prevent severe chronic tissue damage, offering a promising adjunct approach to improve the prognosis for ChD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.